Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

UroGen Pharma (URGN) Assets Average (2019 - 2025)

Historic Assets Average for UroGen Pharma (URGN) over the last 9 years, with Q3 2025 value amounting to $196.9 million.

  • UroGen Pharma's Assets Average fell 3255.08% to $196.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $196.9 million, marking a year-over-year decrease of 3255.08%. This contributed to the annual value of $232.0 million for FY2024, which is 4781.07% up from last year.
  • According to the latest figures from Q3 2025, UroGen Pharma's Assets Average is $196.9 million, which was down 3255.08% from $228.2 million recorded in Q2 2025.
  • Over the past 5 years, UroGen Pharma's Assets Average peaked at $293.8 million during Q4 2024, and registered a low of $104.2 million during Q2 2023.
  • In the last 5 years, UroGen Pharma's Assets Average had a median value of $144.5 million in 2023 and averaged $175.9 million.
  • In the last 5 years, UroGen Pharma's Assets Average tumbled by 4058.79% in 2021 and then skyrocketed by 13158.34% in 2024.
  • Quarter analysis of 5 years shows UroGen Pharma's Assets Average stood at $127.2 million in 2021, then grew by 3.83% to $132.0 million in 2022, then skyrocketed by 40.84% to $186.0 million in 2023, then surged by 58.0% to $293.8 million in 2024, then plummeted by 32.99% to $196.9 million in 2025.
  • Its last three reported values are $196.9 million in Q3 2025, $228.2 million for Q2 2025, and $266.7 million during Q1 2025.